Skip to content

Cortisol and Food Insecurity

Food Insecurity, Poor Diet, and Metabolic Syndrome: Cortisol's Amplifying Role

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05191030
Enrollment
453
Registered
2022-01-13
Start date
2022-03-11
Completion date
2025-09-23
Last updated
2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Insecurity

Keywords

Food insecurity, Physiological Stress, Psychological Stress, Cortisol, Eating, Diet

Brief summary

This study used a within-subjects design in a sample of individuals with a range of food insecurity recruited from the Los Angeles community (N = 400; 44.5% men). These participants then, in counterbalanced order, were exposed to a gold-standard laboratory stressor and a control condition, one month apart. Moderation analyses will test whether cortisol reactivity to the stressor acts as a modulator of the relationship between high levels of food insecurity and increased hyperpalatable food intake.

Interventions

BEHAVIORALHigh-Stress Intervention

Those undergoing the High-Stress will be exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993), which reliably induces cortisol reactivity in most individuals.

Sponsors

University of California, Los Angeles
Lead SponsorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Intervention model description

The study is a within-subjects experiment. The order in which participants underwent the experimental or control conditions/arms was counterbalanced. 50% of participants underwent the experimental condition first and then the control condition, one month later. The rest of the sample underwent the control condition first then the experimental condition, one month later.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age 18+ * English-speaking

Exclusion criteria

* Recent (\<1 year) diagnosis of major psychiatric disorders including any mood disorder, schizophrenia, or PTSD * Recent (\<1 year) diagnosis of eating disorder * Recent (\<1 year) diagnosis of metabolic or endocrine disorder or steroid or hormonal contraceptive use * Pregnancy * Allergy to any of the foods in the food buffet * Participation in strict dieting or caloric restriction

Design outcomes

Primary

MeasureTime frameDescription
Hyperpalatable Food Intake Measured in KilocaloriesHyperpalatable food intake was measured twice: 5 minutes following the experimental (high stress) or control condition during the first visit, and again 5 minutes following the alternate condition during the second visit.The primary outcome was hyperpalatable food intake, initially measured in grams and converted into kilocalories. The food consisted of the following items: donuts, M\&Ms, potato chips, crackers, and Sprite. These foods were chosen because processed foods, added sugars, refined grains, starchy vegetables, and sugar sweetened beverages are foods to avoid according to the 2019 American Diabetes Association Nutrition Consensus Report and are high in carbohydrates and glycemic index.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORA. Janet Tomiyama, Ph.D.

University of California, Los Angeles

Baseline characteristics

Characteristic
Age, Continuous34.52 Years
STANDARD_DEVIATION 13.776
Race/Ethnicity, Customized
Asian
93 Participants
Race/Ethnicity, Customized
Black or African American
23 Participants
Race/Ethnicity, Customized
Hispanic or Latino/a/x
109 Participants
Race/Ethnicity, Customized
More than One Race
10 Participants
Race/Ethnicity, Customized
Other
2 Participants
Race/Ethnicity, Customized
White
115 Participants
Sex/Gender, Customized
Men
91 Participants
Sex/Gender, Customized
Non-Binary/Other
19 Participants
Sex/Gender, Customized
Women
102 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 4000 / 400
other
Total, other adverse events
0 / 4000 / 400
serious
Total, serious adverse events
0 / 4000 / 400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026